Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Metropolis HealthcareNSE:METROPOLIS +1.90%93 5-Year Yield-on-Cost % is 0.33 as of Sep. 22, 2026, which is 18% below its 10-year median of 0.40. GuruFocus rates NSE:METROPOLIS with a GF Score™ of 93/100 and a GF Value™ of ₹607.77 (Fairly Valued). The stock has 5 warning signs investors should review. Among 61 Medical Diagnostics & Research companies, Metropolis Healthcare ranks worse than 88.52% on this metric.
Metropolis Healthcare's yield on cost for the quarter that ended in Jun. 2026 was 0.33.
The historical rank and industry rank for Metropolis Healthcare's 5-Year Yield-on-Cost % or its related term are showing as below:
NSE:METROPOLIS'
s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 0.18 Med: 0.4 Max: 0.8
Current: 0.33
During the past 13 years, Metropolis Healthcare's highest Yield on Cost was 0.80. The lowest was 0.18. And the median was 0.40.
NSE:METROPOLIS's 5-Year Yield-on-Cost % is ranked worse than 88.52% of 61
companies
in the Medical Diagnostics & Research industry
Industry Median: 2.63
vs NSE:METROPOLIS: 0.33
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
Metropolis Healthcare 5-Year Yield-on-Cost % Related Terms
NSE:METROPOLIS vs TMO, DHR, NTRA: 5-Year Yield-on-Cost % Comparison
For the Diagnostics & Research subindustry, Metropolis Healthcare's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Metropolis Healthcare 5-Year Yield-on-Cost % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Metropolis Healthcare's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where Metropolis Healthcare's 5-Year Yield-on-Cost % falls into.
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
Metropolis Healthcare (NSE:METROPOLIS) has a 5-Year Yield-on-Cost % of 0.33 as of Sep. 22, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Metropolis Healthcare and its competitors. This is 18% below median its historical median of 0.40. Over the past decade, Metropolis Healthcare's 5-Year Yield-on-Cost % has ranged from 0.18 to 0.80. According to the industry distribution chart, Metropolis Healthcare ranks #54 out of 61 companies in the Medical Diagnostics & Research industry, placing it in the top 88.5%.
Is Metropolis Healthcare's 5-Year Yield-on-Cost % too high?
Metropolis Healthcare's current 5-Year Yield-on-Cost % of 0.33 is 18% below median its 10-year median of 0.40. Over the past 10 years, this metric has ranged from a low of 0.18 to a high of 0.80. The Medical Diagnostics & Research industry median 5-Year Yield-on-Cost % is 2.63. Metropolis Healthcare's value of 0.33 is 87.5% below this industry median. Based on the distribution chart, Metropolis Healthcare ranks #54 out of 61 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Metropolis Healthcare has a GF Score™ of 93/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Metropolis Healthcare's 5-Year Yield-on-Cost % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Metropolis Healthcare ranks #54 out of 61 companies for 5-Year Yield-on-Cost %. This places Metropolis Healthcare in the lower half of its industry. The industry median 5-Year Yield-on-Cost % is 2.63. Metropolis Healthcare's value of 0.33 is 87.5% below this benchmark. Historically, Metropolis Healthcare's own 5-Year Yield-on-Cost % has ranged from 0.18 to 0.80 over the past decade. While the company's 10-year median is 0.40 vs. the industry median of 2.63, Metropolis Healthcare has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Medical Diagnostics & Research company?
The median 5-Year Yield-on-Cost % among Medical Diagnostics & Research companies is 2.63, based on 61 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Metropolis Healthcare's current 5-Year Yield-on-Cost % of 0.33 is 87.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Metropolis Healthcare and its competitors. For the Medical Diagnostics & Research industry, the median 5-Year Yield-on-Cost % is 2.63 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Metropolis Healthcare's current 5-Year Yield-on-Cost % is 0.33, which is 18% below median its own 10-year median of 0.40. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Metropolis Healthcare stock overvalued right now?
Based on GuruFocus' analysis, Metropolis Healthcare (NSE:METROPOLIS) is currently considered Fairly Valued. The stock's GF Value™ is ₹607.77, compared to a current price of ₹593.40 — trading 2.4% below its estimated fair value. The current 5-Year Yield-on-Cost % is 0.33, which is 18% below median its 10-year median of 0.40 and 87.5% below the Medical Diagnostics & Research industry median of 2.63. Metropolis Healthcare's overall GF Score™ is 93/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For Metropolis Healthcare (NSE:METROPOLIS), the current 5-Year Yield-on-Cost % is 0.33 as of Sep. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Metropolis Healthcare (NSE:METROPOLIS) Overvalued in 2026?
Based on GuruFocus' analysis, Metropolis Healthcare stock appears to be undervalued.
The current stock price of ₹593.40 is trading 2.4% below its estimated GF Value™ of ₹607.77.
GuruFocus considers Metropolis Healthcare to be Fairly Valued.
Key valuation signals for NSE:METROPOLIS:
5-Year Yield-on-Cost %: 0.33 (18% below median its 10-year median of 0.40)
GF Value™: ₹607.77 vs. price of ₹593.40 (2.4% below fair value)
Industry Position: 87.5% below the Medical Diagnostics & Research median (#54 of 61)
No single metric tells the full story. See the NSE:METROPOLIS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Metropolis Healthcare Ltd is a diagnostic company in India. It offers a comprehensive range of clinical laboratory tests and profiles, which are used for the prediction, early detection, diagnostic screening, confirmation, and monitoring of the disease. It also offers analytical and supports services to clinical research organizations for their clinical research projects. Pathology service is the only principal activity and reportable segment from which the Group generates its revenue.
93GF Score
Get the complete analysis for NSE:METROPOLIS
5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:METROPOLIS has been successfully added to your 
